Amgen could reach settlement with FTC over Horizon in next few weeks - report
Mario Tama
Amgen (NASDAQ:AMGN) could come to a settlement with the Federal Trade Commission over its planned $28 billion acquisition of Horizon Therapeutics (NASDAQ:HZNP) in the next couple weeks after the FTC paused the in-house challenge to the deal.
The $116.50 per share purchase could close in about a month, according to CNBC's David Faber. The FTC staff and Amgen (AMGN) have "essentially" agreed to a settlement, where Amgen has agreed to never bundle Horizon's Tepezza or Krystexxa drugs.
The "FTC motion to suspend suit against Amgen serves as a positive indicator for the closing of the Horizon deal," BMO analyst Evan David Seigerman, who has a market perform rating and a $260 price target on Amgen (NASDAQ:AMGN), wrote in a note on Sunday.
Horizon's (HZNP) shares rose 5.7% on Monday.

More on Amgen, Horizon Therapeutics, etc.

Horizon Therapeutics: Can Investors Profit From Amgen Deal Confusion?
Improved Outlook For Horizon Therapeutics And Amgen
Amgen Is Back!
Amgen Gives You Growth, Dividend Growth, And Value
Amgen Inc. 2023 Q2 - Results - Earnings Call Presentation

Amgen Inc. (AMGN) Q2 2023 Earnings Call Transcript
Amgen: Huge Potential With Biosimilars And GLP-1
Amgen: Is The 3.79% Dividend Yield Worth The Fuss?
FTC likely to lose its challenge to the Horizon/Amgen deal, legal experts say - analyst
Amgen says FTC case to block Horizon Therapeutics deal `defies logic'
Horizon Therapeutics gains amid speculation on potential FTC settlement on Amgen